Merck & Co., Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Merck & Co., Inc. (MRK) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 108.90% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-08-07
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2026-06-30 was 108.90%.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2026-03-31 was 33.10%.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2024-09-30 was 7.20%.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2024-03-31 was 1.60%.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2012 was 0.50%.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2011 was -0.10%, a 100.34% decline from fiscal 2010.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2010 was 29.30%.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2009 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|---|---|---|
| 2026-06-30 | 108.90% 10-Q · filed 2026-08-07 | 45.30% 10-Q · filed 2026-08-07 | ||
| 2026-03-31 | 33.10% 10-Q · filed 2026-05-04 | |||
| 2024-09-30 | 7.20% 10-Q · filed 2025-11-05 | 2.10% 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 0.70% 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | 1.60% 10-Q · filed 2025-05-02 | |||
| 2023-09-30 | 44.00% 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 25.10% 10-Q · filed 2024-08-05 | 101.90% 10-Q · filed 2024-08-05 | ||
| 2012-12-31 | 0.50% 10-K · filed 2013-02-28 | |||
| 2011-12-31 | -0.10% 10-K · filed 2013-02-28 | |||
| 2010-12-31 | 29.30% 10-K · filed 2013-02-28 | |||
| 2009-12-31 | 0.00% 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |